Tau(t)ing glucocorticoid binding.
作者信息
Vettorazzi Sabine, Tuckermann Jan
机构信息
Institute of Comparative Molecular Endocrinology, Ulm University, Ulm, Baden-Württemberg, Germany.
出版信息
Cell Res. 2025 Jan;35(1):1-2. doi: 10.1038/s41422-024-01041-z.
Abstract
摘要
相似文献
1
Tau(t)ing glucocorticoid binding.tau（τ）与糖皮质激素结合。
Cell Res. 2025 Jan;35(1):1-2. doi: 10.1038/s41422-024-01041-z.
2
Glucocorticoid hormone binding to rat adipocytes.
Biochim Biophys Acta. 1994 Oct 20;1224(1):17-21. doi: 10.1016/0167-4889(94)90108-2.
3
Glucocorticoid-driven mitochondrial damage stimulates Tau pathology.糖皮质激素驱动的线粒体损伤刺激 Tau 病理。
Brain. 2023 Oct 3;146(10):4378-4394. doi: 10.1093/brain/awad127.
4
Clinical activity of 9-ING-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3β) inhibitor, in refractory adult T-Cell leukemia/lymphoma.9-ING-41 是一种小分子选择性糖原合酶激酶-3β（GSK-3β）抑制剂，在难治性成人 T 细胞白血病/淋巴瘤中的临床活性。
Cancer Biol Ther. 2022 Dec 31;23(1):417-423. doi: 10.1080/15384047.2022.2088984.
5
FISH-ing Novel Dynamic Modes of Glucocorticoid-Induced Chromatin Reorganization.FISH 钓取糖皮质激素诱导的染色质重排的新型动态模式。
Trends Endocrinol Metab. 2018 Apr;29(4):204-207. doi: 10.1016/j.tem.2018.02.003. Epub 2018 Feb 21.
6
Mechanism of synergistic transcriptional transactivation by the human glucocorticoid receptor.人糖皮质激素受体协同转录反式激活的机制
Proc Natl Acad Sci U S A. 1991 Oct 1;88(19):8283-7. doi: 10.1073/pnas.88.19.8283.
7
Identification of amino acids in the tau 2-region of the mouse glucocorticoid receptor that contribute to hormone binding and transcriptional activation.鉴定小鼠糖皮质激素受体tau 2区域中有助于激素结合和转录激活的氨基酸。
Mol Endocrinol. 1997 Nov;11(12):1795-805. doi: 10.1210/mend.11.12.0018.
8
Direct interaction of the tau 1 transactivation domain of the human glucocorticoid receptor with the basal transcriptional machinery.人糖皮质激素受体的tau 1反式激活结构域与基础转录机制的直接相互作用。
Mol Cell Biol. 1993 Jan;13(1):399-407. doi: 10.1128/mcb.13.1.399-407.1993.
9
Modulation of thyroid hormone-dependent gene expression in Xenopus laevis by INhibitor of Growth (ING) proteins.ING 蛋白对非洲爪蟾甲状腺激素依赖基因表达的调控。
PLoS One. 2011;6(12):e28658. doi: 10.1371/journal.pone.0028658. Epub 2011 Dec 5.
10
Role of important hydrophobic amino acids in the interaction between the glucocorticoid receptor tau 1-core activation domain and target factors.重要疏水氨基酸在糖皮质激素受体tau 1-核心激活域与靶因子相互作用中的作用
Biochemistry. 1998 Jun 30;37(26):9586-94. doi: 10.1021/bi973029x.
引用本文的文献
1
Inflammation-modulating polymeric nanoparticles: design strategies, mechanisms, and therapeutic applications.炎症调节聚合物纳米颗粒：设计策略、作用机制及治疗应用
EBioMedicine. 2025 Jul 3;118:105837. doi: 10.1016/j.ebiom.2025.105837.
本文引用的文献
1
Journey through discovery of 75 years glucocorticoids: evolution of our knowledge of glucocorticoid receptor mechanisms in rheumatic diseases.75 年探索之旅：糖皮质激素——我们对风湿性疾病中糖皮质激素受体机制认识的演变。
Ann Rheum Dis. 2024 Nov 14;83(12):1603-1613. doi: 10.1136/ard-2023-225371.
2
Nationwide prevalence of glucocorticoid prescriptions over 17 years and osteoporosis prevention among long-term users.17年间全国糖皮质激素处方的流行情况及长期使用者的骨质疏松预防
SAGE Open Med. 2024 Mar 20;12:20503121241235056. doi: 10.1177/20503121241235056. eCollection 2024.
3
Glucocorticoids employ the monomeric glucocorticoid receptor to potentiate vitamin D and parathyroid hormone-induced osteoclastogenesis.糖皮质激素利用单体糖皮质激素受体增强维生素 D 和甲状旁腺激素诱导的破骨细胞生成。
FASEB J. 2019 Dec;33(12):14394-14409. doi: 10.1096/fj.201802729RRR. Epub 2019 Nov 14.
4
11β-HSD1 plays a critical role in trabecular bone loss associated with systemic glucocorticoid therapy.11β-HSD1 在与全身糖皮质激素治疗相关的小梁骨丢失中发挥关键作用。
Arthritis Res Ther. 2019 Aug 16;21(1):188. doi: 10.1186/s13075-019-1972-1.
5
Cortical bone loss caused by glucocorticoid excess requires RANKL production by osteocytes and is associated with reduced OPG expression in mice.糖皮质激素过量引起的皮质骨丢失需要骨细胞产生核因子κB受体活化因子配体（RANKL），并且与小鼠骨保护素（OPG）表达降低有关。
Am J Physiol Endocrinol Metab. 2016 Sep 1;311(3):E587-93. doi: 10.1152/ajpendo.00219.2016. Epub 2016 Jul 26.
6
Glucocorticoids suppress bone formation by attenuating osteoblast differentiation via the monomeric glucocorticoid receptor.糖皮质激素通过单体糖皮质激素受体抑制成骨细胞分化来抑制骨形成。
Cell Metab. 2010 Jun 9;11(6):517-31. doi: 10.1016/j.cmet.2010.05.005.
7
Glucocorticoids act directly on osteoclasts to increase their life span and reduce bone density.糖皮质激素直接作用于破骨细胞，以延长其寿命并降低骨密度。
Endocrinology. 2006 Dec;147(12):5592-9. doi: 10.1210/en.2006-0459. Epub 2006 Aug 24.
8
Glucocorticoids suppress bone formation via the osteoclast.糖皮质激素通过破骨细胞抑制骨形成。
J Clin Invest. 2006 Aug;116(8):2152-60. doi: 10.1172/JCI28084. Epub 2006 Jul 27.
9
Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study.社区中口服糖皮质激素的使用与继发性骨质疏松症的预防：一项横断面研究。
BMJ. 1996 Aug 10;313(7053):344-6. doi: 10.1136/bmj.313.7053.344.
Zotero 插件